Ketamine

Ketamine is a medication classed as a dissociative anesthetic and belongs chemically to the arylcyclohexylamine family, being derived from a cyclohexanone structure ^[1]. It is a racemic drug, made up of two enantiomers, the S-form known as esketamine and the R-form known as arketamine, which differ in their potency at the drug's main target ^[2]. Beyond anesthesia it has analgesic and, at lower doses, psychoactive and hallucinogenic properties ^[1].

Ketamine was first synthesized in 1962 by the chemist Calvin Stevens while consulting for the Parke-Davis company, and it carried the developmental code CI-581 ^[1]. It was created as a shorter-acting, less disturbing alternative to phencyclidine, and the term dissociative anesthesia was coined to describe the peculiar detached state it produced ^[1]. The drug was approved for use in the United States in 1970 and saw extensive use as a battlefield anesthetic during the Vietnam War, valued because it did not depress breathing the way many anesthetics do ^[1].

In clinical practice ketamine is used to induce and maintain anesthesia, for sedation during procedures, and for pain control, and it is especially useful in trauma, emergency, and pediatric settings and where preserving spontaneous breathing is important ^[1]. Around the year 2000, researchers discovered that low doses could rapidly relieve severe depression, an effect that unfolds within hours; this led to the 2019 approval of an esketamine nasal spray, marketed as Spravato, for treatment-resistant depression, given together with an oral antidepressant ^[2][4]. Ketamine is also used off-label for chronic pain and has been explored in conditions such as status epilepticus ^[1].

The drug's central mechanism is blockade of the NMDA glutamate receptor, which underlies both its anesthetic action and, through downstream effects on synaptic plasticity, its antidepressant action ^[3][4]. At sub-anesthetic doses ketamine is also used recreationally for its dissociative and euphoric effects; heavy use can lead to an intense state of detachment colloquially called the K-hole, and it carries risks of tolerance and psychological dependence ^[4].

Ketamine is a controlled substance in many jurisdictions; in the United States it has been listed as a Schedule III substance since 1999, and other countries impose their own restrictions ^[1]. It is available as an injectable solution and in other forms, and the approved antidepressant is delivered as a nasal spray ^[1][2]. Common short-term adverse effects include nausea, vomiting, and emergence reactions such as confusion or hallucination as the drug wears off, while long-term heavy use is associated with bladder and urinary tract damage, liver injury, and cognitive problems ^[1][4].

Ketamine belongs in a supervised setting, and the reasons divide cleanly into what happens during a dose and what happens with repeated unsupervised use.

Acutely it causes dissociation, raises blood pressure and heart rate, and commonly brings nausea, dizziness and confusion; emergence reactions as it wears off are a recognised part of the drug rather than a complication. That profile is exactly why sessions are monitored and why the approved nasal spray carries a two-hour observation period ^[33].

The serious long-term harms sit with heavy, frequent recreational use rather than with clinical courses. Ketamine-induced ulcerative cystitis is real, well characterised and can be severely disabling, involving genuine damage to the bladder and urinary tract; it was described as a distinct clinical entity in 2007 and heavy users are the population at risk. Cognitive and memory impairment is documented in the same population, and a one-year longitudinal study of frequent users found deficits that tracked the amount used ^[30]. Psychological dependence is a real outcome and the drug has clear abuse potential.

Repeated supervised courses for depression have not so far produced that picture, and long-term follow-up of esketamine has not shown cystitis or cognitive decline; that reflects intermittent monitored dosing rather than any inherent safety, and the follow-up period is shorter than the way the drug is now used ^[33][34]. For depression it should run through a clinic with proper screening. This entry is educational, not medical advice, and there is no sourcing guidance here.

Ketamine adds to the sedation and respiratory depression of other CNS depressants including benzodiazepines, opioids, barbiturates, and alcohol; benzodiazepines in particular have been shown to blunt and shorten its antidepressant response. It is metabolized largely by CYP3A4 and CYP2B6, so inhibitors (clarithromycin, ticlopidine) raise exposure while inducers (rifampin) lower it. Combining ketamine with sympathomimetics or with monoamine oxidase inhibitors can produce additive hypertension and tachycardia, a concern given ketamine's own cardiovascular stimulation, and theophylline or aminophylline may lower the seizure threshold. Concurrent serotonergic agents raise a theoretical serotonin-toxicity concern that is not well established. This is research information, not medical advice.

Checking a whole stack? Run it through interactions + stacks.

Ketamine was synthesized in 1962 by the chemist Calvin Stevens at Parke-Davis, where it carried the development code CI-581 and was pursued as a shorter-acting, less psychotomimetic successor to phencyclidine. The first human studies were run in 1964 by Edward Domino and Guenter Corssen at the University of Michigan, and it was Domino's wife who proposed the term dissociative anesthetic for the detached state it produced. It received United States approval in 1970 as Ketalar, and saw heavy use as a field and battlefield anesthetic, including in Vietnam, valued for a wide safety margin and for not depressing respiration the way alternatives did ^[1].

A recreational following developed through the following decades, and with it the first reports of the harms that heavy use causes. Ketamine-associated ulcerative cystitis was described as a distinct clinical entity in 2007, which reframed the drug's risk profile around the bladder rather than around acute overdose.

The modern chapter began around 2000, when small studies found that sub-anesthetic doses relieved severe depression within hours ^[3]. That produced a decade of trials, a proliferation of infusion clinics operating off-label, and eventually a licensed product: the esketamine nasal spray, approved in the United States in 2019 for treatment-resistant depression alongside an oral antidepressant ^[2]. Since 2016 the mechanistic argument has moved to whether the antidepressant effect requires NMDA blockade at all, after a Nature report attributed it to a downstream metabolite instead ^[23]; that question is still open.

Few drugs carry three reputations this separate. In anesthesia it is a workhorse valued precisely for being unglamorous: it maintains blood pressure and respiration where other agents do not, which makes it the choice in trauma, in the field, in paediatric procedures and wherever an airway cannot be guaranteed ^[1]. In psychiatry it is the compound that broke a fifty-year monoamine consensus, and the enthusiasm around it is genuine and evidence-backed while also having outrun the evidence in places; the infusion-clinic industry that grew up around off-label use is far larger than the trial base that justifies any particular protocol ^[34]. Recreationally it has a reputation for being comparatively forgiving in the short term, which is true of a single occasion and badly misleading over time, because the harm that actually accrues is bladder damage and cognitive impairment from frequency rather than anything dramatic from one dose ^[30].

The most common misconception in each direction is worth naming. Clinically, that the antidepressant effect is durable on its own; it is rapid but generally requires a maintenance plan. Recreationally, that the absence of a hangover means the absence of a cost. Among people reading about mechanisms, that NMDA blockade is the settled explanation; that is the part the field itself is least sure of ^[26].